{
	"kj8twn8wText": "*Side effects associated with Brintellix® were compar<span class=\"_ _0\"></span>ed with those of the SSRIs escitalopram and paroxetine and with those of the SNRI Venlafaxine.<br>**F<span class=\"_ _2\"></span>or the 20 mg/day dose, an increase in treatment-emer<span class=\"_ _0\"></span>gent sexual dysfunction was seen compared to placebo.<span class=\"_ _0\"></span> Please refer to the full Summary of Product <br>Char<span class=\"_ _0\"></span>acteristics or Prescribing Informa<span class=\"_ _0\"></span>tion for further information on safety and tolerability.",
	"kj8twn8xText": "Bri<span class=\"_ _0\"></span>nte<span class=\"_ _0\"></span>lli<span class=\"_ _0\"></span>x® d<span class=\"_ _0\"></span>oe<span class=\"_ _0\"></span>s not e<span class=\"_ _2\"></span>xhib<span class=\"_ _0\"></span>it ma<span class=\"_ _0\"></span>n<span class=\"_ _0\"></span>y of the si<span class=\"_ _0\"></span>de <br><span class=\"ls4 ws16\">ef<span class=\"_ _b\"></span>fec<span class=\"_ _1\"></span>t<span class=\"_ _1\"></span>s<span class=\"_ _1\"></span> t<span class=\"_ _1\"></span>y<span class=\"_ _1\"></span>pical o<span class=\"_ _1\"></span>f SSRIs<span class=\"_ _1\"></span> and<span class=\"_ _1\"></span> SNRIs<span class=\"_ _0\"></span>*<span class=\"_ _1\"></span> including<span class=\"_\"> </span> <br>sexual d<span class=\"_ _1\"></span>ys<span class=\"_ _1\"></span>func<span class=\"_ _b\"></span>tion<span class=\"_ _0\"></span>**<span class=\"_ _1\"></span> and<span class=\"_ _1\"></span> weight gain<span class=\"_ _30\"></span><span class=\"fs2 ls2a ws60 v1\">1-<span class=\"_ _b\"></span>4</span></span>",
	"kj8twn8yText": "W<span class=\"_ _0\"></span>eight neutral",
	"kj8twn8zText": "Mild to moderate ",
	"kj8twn90Text": "transient nausea",
	"kj8twn91Text": "Sleep disturbance ",
	"kj8twn92Text": "at placebo level",
	"kj8twn93Text": "Low potential for ",
	"kj8twn94Text": "drug-drug interactions",
	"kj8twn95Text": "Sexual dysfunction at ",
	"kj8twn96Text": "placebo level**",
	"kj8twn97Text": "Low ra<span class=\"_ _0\"></span>te of<span class=\"_ _1\"></span> trea<span class=\"_ _0\"></span>tment ",
	"kj8twn98Text": "emergent adverse events",
	"kj8twn99Text": "Low withdrawal r<span class=\"_ _0\"></span>ate ",
	"kj8twn9aText": "and discontinuation",
	"kj8twn9bText": " Low ra<span class=\"_ _0\"></span>te of<span class=\"_ _1\"></span> safety-rela<span class=\"_ _0\"></span>ted ",
	"kj8twn9cText": "adverse events",
	"kj8twn9dText": "Comparison<span class=\"_ _6f\"></span><span class=\"ff1 fc3 wsa\">Generally well tolerated</span>",
	"Brintellix_55d83a2581": "",
	"Brintellix_55f210959d": "",
	"Brintellix_555ebf9ed6": "",
	"Brintellix_553c3f8e04": "",
	"Brintellix_554c1906ee": "",
	"Brintellix_5587206ceb": "",
	"Brintellix_554965e2d5": "",
	"Brintellix_5573e91b4a": "",
	"Brintellix_5569bb49da": "",
	"Brintellix_55c9b3a4fd": "",
	"Brintellix_55e071515d": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: #f28700; \">\n<font style=\"font-size: 15px;\">Study Design</font>\n</span>",
	"Brintellix_55470cc4d0": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); \">\n<font style=\"font-size: 22.5px;\">Weight neutral</font>\n</span>",
	"Brintellix_55928e5e66": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 20px; color: #645e5e;display:block;\">\n<font style=\"font-size: 20px;\">\nBrintellix<sup>®</sup> had no effect relative to placebo on body weight in clinical short- and long-term studies<sup>1</sup>\n</font>\n</span>",
	"Brintellix_5557caf76e": "<span style=\"font-family: &quot;3_CCMVBT+AvenirNextLTPro-Demi&quot;; color: #f28700;\">\n<font style=\"font-size: 20px;\">Mean weight increase in patients treated with Brintellix<sup>®</sup> for up to <br>12 months<sup>1</sup></font>\n</span>",
	"Brintellix_554cf64ad9": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 13px; color: #645e5e;display:block;\">\n<font style=\"font-size: 11.2px;\">\nFrom an analysis designed to assess the tolerability and safety in Brintellix® in 11 randomised, double-blind, placebo-controlled, short-term studies in MDD and five long-term studies. Ten of the short-term studies included participants aged 18-75, and one included only participants aged over 65.&nbsp;</font></span><span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 13px; color: #645e5e;display:block;\"><font style=\"font-size: 11.2px;\"><b>&nbsp;1.</b> Baldwin DS et al. J Psychopharmacol 2016;30:242-252.\n</font>\n</span>",
	"Brintellix_55355a172a": "<span style=\"font-family: &quot;3_CCMVBT+AvenirNextLTPro-Demi&quot;; color: #fff; text-align:center;display:block\">\n<font style=\"font-size: 25px;\">Less than 1kg<br>weight changes</font>\n</span>",
	"Brintellix_55bc240218": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(242, 135, 0); line-height: 1;\"><div style=\"text-align: center; padding-top: 8px;\"><span style=\"font-size: 19px;\">Low incidence of</span></div>\n<font style=\"font-size: 19px;\"><div style=\"text-align: center;\">discontinuation symptoms</div></font></span>",
	"Brintellix_5552c8ce91": "<span style=\"font-family: &quot;3_CCMVBT+AvenirNextLTPro-Demi&quot;; color: #4d7f86;\"><div style=\"text-align: center;padding-top:19px;\"><span style=\"font-size: 19px;\">Low withdrawal rate</span></div>\n</span>",
	"Brintellix_55ff33ee66": "<span style=\"font-family: &quot;3_CCMVBT+AvenirNextLTPro-Demi&quot;; color: #645e5e; text-align:center;\">\n<font style=\"font-size: 16px;\">Incidence of discontinuation symptoms with Brintellix<sup>®</sup> is similar to that of placebo<sup>1</sup></font>\n</span>",
	"Brintellix_55a4037686": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); \"><div style=\"text-align: center;\"><span style=\"font-size: 15px;\">Discontinuation-emergent signs and symptoms (DESS) total score from&nbsp;</span></div>\n<font style=\"font-size: 15px;\"><div style=\"text-align: center;\">three placebo-controlled duloxetine-referenced studies in MD</div></font></span>",
	"Brintellix_553d735b1f": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: #f28700; \">\n<font style=\"font-size: 13px;\">Study Design</font>\n</span>",
	"Brintellix_551b1417d9": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); \">\n<font style=\"font-size: 15px;\">Mean DESS total score</font>\n</span>",
	"Brintellix_55577ba8af": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block; text-align: center;\">\n<font style=\"font-size: 12.5px;\">\nWeek 8<br style=\"\">\n(Baseline)\n</font>\n</span>",
	"Brintellix_5591b7b119": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block; text-align: center;\">\n<font style=\"font-size: 12.5px;\">\nWeek 9<br>\n(Week 1 of discontinuation)\n</font>\n</span>",
	"Brintellix_5509b2927a": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block; text-align: center;\">\n<font style=\"font-size: 12.5px;\">\nWeek 10<br>\n(Week 2 of discontinuation)\n</font>\n</span>",
	"Brintellix_5548312990": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 11.5px;\">\nDuloxetine was included as an active reference for study validation, not for comparison of effect size. <br>\n<b>1.</b> Baldwin DS et al. J Psychopharmacol 2016;30:242-252.\n</font>\n</span>",
	"Brintellix_55f40bc8a9": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); \"><div style=\"text-align: center;\"><span style=\"font-size: 14px;\">TEAEs in 11 short-term studies in patients with MDD:</span></div>\n<font style=\"font-size: 14px;\"><div style=\"text-align: center;\">\npercentage of patients with TEAEs (≥0.5%) leading to withdrawal (APTS)<sup>1</sup></div></font></span>",
	"Brintellix_556473702d": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: #f28700; \">\n<font style=\"font-size: 13px;\">Study Design</font>\n</span>",
	"Brintellix_55775c36ac": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); \"><div style=\"text-align: center;\"><span style=\"font-size: 15px; background-color: transparent;\">Patients withdrawn due to&nbsp;</span></div>\n<font style=\"font-size: 15px;\"><div style=\"text-align: center;\"><span style=\"background-color: transparent;\">TEAEs (%)</span></div></font></span>",
	"Brintellix_55970c6085": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 0.9; color: rgb(100, 94, 94); display: block;\"><font style=\"font-size: 11px;\">From an analysis designed to assess the tolerability and safety in Brintellix® in 1.1 randomised, double-blind placebo-controlled short-term studies. <br>\nDuloxetine and venlafaxine were included as active references for study validation, not for comparison of effect size. ATPS, all patients treated set.\n</font>\n</span><span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1.5; color: rgb(100, 94, 94); display: block;\"><font style=\"font-size: 11px;\"><b>1.</b> Baldwin DS et al. J Psychopharmacol 2016;30:242-252.<br></font></span>",
	"Brintellix_554c9b1d58": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;\">\n<font style=\"font-size: 22.5px;\">Incidence of treatment-emergent sexual dysfunction with Brintellix® is at placebo level<sup style=\"\">†1</sup></font>\n</span>",
	"Brintellix_5565f4818a": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 16.5px;\">\nSexual dysfunction is an underreported yet important adverse effect of antidepressants,<sup>2</sup><br>\noccurring in up to 71% of patients<sup>3</sup> and accounting for up to 22% of treatment<br>discontinuations<sup>4</sup>\n</font>\n</span>",
	"Brintellix_55cfb9e427": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 16.5px;\">\nIn the MDD 6-8 week controlled trials of Brintellix<sup>®</sup>, spontaneous reported adverse<br>reactions related to sexual dysfunction were captured as individual event terms<sup>5</sup>\n</font>\n</span>",
	"Brintellix_55090f33e8": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: #645e5e; \">\n<font style=\"font-size: 15px;\">Females</font>\n</span>",
	"Brintellix_550ef08a6b": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: #645e5e; \"><font style=\"font-size: 15px;\">Males</font>\n</span>",
	"Brintellix_55f189ab5e": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; color: rgb(100, 94, 94); line-height: 1;display:block;\"><font style=\"font-size: 11.5px;\"><sup>†</sup>For the 20 mg/day dose, an increase in TESD was seen compared to placebo. TESD, treatment-emergent sexual dysfunction. <br> <br>\n\t<b>1.</b> Brintellix<sup>®</sup> Summary of Product Characteristics. 2021. <b>2.</b> Llorca PM et al. Curr MedRes Opin 2014;30:12,2589-2606.&nbsp;<b>3.</b> Clayton AH et al. Expert Opin\nDrug Saf 2014;13:1361-1374. <b>4.</b> Thase ME et al. Eur Neuropsychopharmacol 2017;27:773-781. <b>5.</b> Trintellix<sup>®</sup> US Prescribing Information.\n</font>\n</span>",
	"Brintellix_551425056d": "",
	"Brintellix_5510ca87ce": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;\">\n<font style=\"font-size: 22.5px;\">Brintellix<sup>®</sup> maintains efficacy in treating MDD while improving SSRI-induced sexual dysfunction,<sup style=\"\">*3</sup> and is weight neutral<sup style=\"\">**1,4</sup></font>\n</span>",
	"Brintellix_55a7d52822": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(242, 135, 0); line-height: 3;\"><div style=\"text-align: center;\"><span style=\"font-size: 19px;\">Sexual dysfunction</span></div>\n</span>",
	"Brintellix_558fcdf60c": "<span style=\"font-family: &quot;3_CCMVBT+AvenirNextLTPro-Demi&quot;; color: rgb(84, 122, 129); line-height: 3;\"><div style=\"text-align: center;\"><span style=\"font-size: 19px;\">Efficacy compared to Escitalopram</span></div>\n</span>",
	"Brintellix_55cd501fd6": "",
	"Brintellix_557a9fc24a": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\">\n<font style=\"font-size: 15px;\">\n\tMean change from baseline in CSFQ-14\n</font>\n</span>",
	"Brintellix_5527895788": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(100, 94, 94); line-height: 1;display:block;\">\n<font style=\"font-size: 15px;\">\n\tBrintellix<sup>®</sup> is superior to escitalopram at improving SSRI induced TESD<sup>*3</sup>\n</font>\n</span>",
	"Brintellix_55cae19ff2": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: #f28700; \">\n<font style=\"font-size: 15px;\">Study Design</font>\n</span>",
	"Brintellix_55251fd35d": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\"><div style=\"text-align: center;\"><span style=\"font-size: 15px;\">Mean change from baseline</span></div>\n<font style=\"font-size: 15px;\"><div style=\"text-align: center;\">in CSFQ-14 total score</div></font></span>",
	"Brintellix_557435dff7": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\">\n<font style=\"font-size: 15px;\">\n\tWeeks in study\n</font>\n</span>",
	"Brintellix_55db364b31": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; color: rgb(100, 94, 94); line-height: 1;display:block;\">\n<font style=\"font-size: 11.5px;\">\n\t*As measured by CSFQ-14. Previous SSRIs included citalopram, paroxetine or sertraline. In short-term clinical studies, the 20 mg dose of Brintellix<sup>®</sup> was associated with an increase in treatment-emergent sexual dysfunction;<sup>4</sup> **Relative to placebo, in clinical short and long-term studies; <sup>†</sup>p&lt;0.05; <sup>‡</sup>p&lt;0.01 vs. escitalopram. The primary endpoint in Jacobsen PL et al. (2015) was change from baseline in the CSFQ-14 total score after eight weeks of treatment. A further endpoint included change from baseline in MADRS total score. The severity of depressive symptoms for both Brintellix<sup>®</sup>-treated and escitalopram-treated patients remained low (as measured by MADRS).Mean change from baseline in (CSFO-14) total scores during the double-blind treatment period. MMRM, FAS, LS means. CSFQ-14, changes in sexual functioning questionnaire - short form; (sexual pleasure, sexual desire/frequency, sexual desire/interest, sexual arousal, sexual orgasm); FAS, full analysis set; MADRS, Montgomery-Asberg depression rating scale; MMRM, mixed model for repeated measures; LS means, least square means. \n\t<span style=\"display: inline-block;padding-top: 10px;width: 646px;line-height:1.4;\"><b>1.</b> Baldwin DS et al. J Psychopharmacol 2016;30:242-252. <b>2.</b>&nbsp;Brintellix<sup>®</sup> Summary of Product Characteristics. 2021. <b>3.</b> Jacobsen PL et al. J Sex Med 2015;12:2036-2048. <b>4.</b> Alvarez E et al. Int J Neuropsychopharmacol 2012;15:589-600.</span>\n</font>\n</span>",
	"Brintellix_55c917b5a3": "<span style=\"font-family: &quot;3_CCMVBT+AvenirNextLTPro-Demi&quot;; color: rgb(100, 94, 94); line-height: 1;display:block;\">\n<font style=\"font-size: 15px;\">\n\tVortioxetine was superior to escitalopram in improving SSRI-induced treatment-<br>emergent sexual dysfunction while efficacy measured with MADRS was maintained\n</font>\n</span>",
	"Brintellix_558fd18958": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: #f28700; \">\n<font style=\"font-size: 15px;\">Study Design</font>\n</span>",
	"Brintellix_5505d2d114": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\"><div style=\"text-align: center;\"><span style=\"font-size: 15px;\">Mean change from baseline</span></div>\n<font style=\"font-size: 15px;\"><div style=\"text-align: center;\">in MADRS total score</div></font></span>",
	"Brintellix_55fb8cc99e": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\"><div style=\"text-align: center;\"><span style=\"font-size: 15px;\">Weeks</span></div>\n</span>",
	"Brintellix_558a8b926f": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; color: rgb(100, 94, 94); line-height: 1;display:block;\">\n<font style=\"font-size: 11px;\">\n\t The study included well-treated patients with MDD who were in remission for depressive symptoms but were experiencing sexual dysfunction <br>while being treated with citalopram, sertraline or paroxetine <br>\n\t<b>1.</b> Baldwin DS et al. J Psychopharmacol 2016;30:242-252. <b>2.</b>&nbsp;Brintellix® Summary of Product Characteristics. 2021. <b>3.</b> Jacobsen PL et al. J Sex Med 2015;12:2036-2048. <b>4.</b> Alvarez E et al. Int J Neuropsychopharmacol 2012;15:589-600.\n</font>\n</span>",
	"Brintellix_552eccd598": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;\">\n<font style=\"font-size: 22.5px;\">Brintellix® sleep disturbance at placebo level in short term and long term clinical trials<sup style=\"\">1</sup></font>\n</span>",
	"Brintellix_551d1c6290": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 20px;\">\nBrintellix<sup>®</sup> is not associated with sleep disturbance above placebo level<sup>1</sup>\n</font>\n</span>",
	"Brintellix_55d903e01c": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 20px;\">\nBrintellix<sup>®</sup> is not associated with insomnia/</font></span><span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\"><font style=\"font-size: 20px;\">fatigue in short term and long term clinical trials<sup>1</sup>\n</font>\n</span>",
	"Brintellix_553af9a386": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; color: rgb(100, 94, 94); line-height: 1;display:block;\">\n<font style=\"font-size: 11.5px;\">\n\t <b>1.</b>&nbsp;Brintellix<sup>®</sup> Summary of Product Characteristics. 2021.\n</font></span>",
	"Brintellix_558387db39": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;\">\n<font style=\"font-size: 22.5px;\">Mild to moderate nausea</font>\n</span>",
	"Brintellix_5569c3a965": "<span style=\"text-align: left; font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1.2; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 20px;\">\nIt typically occurs within the first two weeks, is usually transient and does not generally lead to treatment discontinuation<sup style=\"\">1,2</sup>\n</font>\n</span>",
	"Brintellix_557b122b8a": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1.2; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 20px;\">\nNausea is the most common adverse event<sup style=\"\">1,2</sup>\n</font>\n</span>",
	"Brintellix_55238d71cd": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: #f28700;\">\n<font style=\"font-size: 22.5px;\">The incidence of<br>nausea associated<br>with Brintellix<sup>®</sup> was<br>dose-dependent<sup>2</sup>\n</font>\n</span>",
	"Brintellix_55a08d9662": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; color: rgb(100, 94, 94); line-height: 1;display:block;\">\n<font style=\"font-size: 11.5px;\">\n\t <b>1. </b>Brintellix<sup>®</sup>  Summary of Product Characteristics. 2021. <b>2.</b> Baldwin DS et al. J Psychopharmacol 2016;30:242-252.\n</font></span>",
	"Brintellix_55190db974": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1.2; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 20px;\">\nIn clinical studies, Brintellix<sup style=\"\">®</sup> had no clinically <br>\nsignificant effect relative to placebo on hepatic or <br>\nrenal assessments, heart rate or blood pressure<sup>1</sup><br>\n<span style=\"display: inline-block;padding-top: 10px;\">Brintellix<sup style=\"\">®</sup> has not shown any clinically significant <br>\neffect on ECG parameters<sup>1,2</sup></span>\n</font>\n</span>",
	"Brintellix_55eb25ca7e": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1.2; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 20px;\">\nIncluding QT, QTc, PR and QRS intervals<br>\n<span style=\"display: inline-block;padding-top: 9px;\">QTc interval prolongation has not been<br>observed in healthy subjects exposed to up to<br>40 mg daily\n</span>\n</font>\n</span>",
	"Brintellix_55043b6017": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; color: rgb(100, 94, 94); line-height: 1;display:block;\">\n<font style=\"font-size: 11.5px;\">\n\t *Brintellix<sup>®</sup> 5 mg-20 mg is the approved dose range for the treatment of adult patients with MDD. <br>\n\t <b>1.</b>&nbsp;Brintellix<sup>®</sup> Summary of Product Characteristics. 2021. <b>2.</b> Wang Y et al. Clin Pharmacol Drug Devel 2013;2:298-309.\n</font>\n</span>",
	"Brintellix_5563bf753f": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1.2; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 20px;\">\nIngestion of Brintellix<sup>®</sup> in the dose range of 40 mg<br>to 75 mg has caused an aggravation of the following<br>adverse reactions: nausea, postural dizziness,<br>diarrhoea, abdominal discomfort, generalised<br>pruritus, somnolence and flushing<sup>*1</sup>\n</font>\n</span>",
	"Brintellix_55a3c9414c": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;\">\n<font style=\"font-size: 22.5px;\">Safety-related adverse events</font>\n</span>",
	"Brintellix_55eb1b6fc6": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;\">\n<font style=\"font-size: 22.5px;\">TEAEs with an incidence of ≥5% in any group during the core <br> treatment period (APTS) in 11 short-term MDD studies<sup>1</sup></font>\n</span>",
	"Brintellix_552a389f82": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(100, 94, 94); line-height: 1;display:block;\">\n<font style=\"font-size: 18px;\">\n\tPreferred Term\n</font>\n</span>",
	"Brintellix_55980f9a91": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; color: rgb(100, 94, 94); line-height: 1;display:block;\">\n<font style=\"font-size: 11.2px;\">\n\t% values in <b>bold </b>are ≥5% and &gt;2x placebo. *Includes the preferred terms: insomnia, initial insomnia, middle insomnia, hyposomnia, sleep disorder, dyssomnia, poor quality sleep and terminal insomnia; **Includes the preferred terms: libido decreased, ejaculation delayed, ejaculation disorder, orgasm abnormal, anorgasmia, disturbance in sexual arousal, ejaculation failure, erectile dysfunction, loss of libido, orgasmic sensation decreased, sexual dysfunction, and vulvovaginal dryness. APTS, all patients treated set; MDD, major depressive disorder; PYE, patient-years of exposure; TEAE, treatment-emergent adverse event. <br>\n\t<b>1.</b> Baldwin DS et al. J Psychopharmacol 2016;30:242-252.\n</font>\n</span>",
	"Brintellix_55b2833a36": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: #f28700; \">\n<font style=\"font-size: 15px;\">Study Design</font>\n</span>",
	"Brintellix_55c1f28f35": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;\">\n<font style=\"font-size: 22.5px;\">Drug-drug interactions</font>\n</span>",
	"Brintellix_55c5b82600": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 19px;\">\nBrintellix<sup>®</sup> has a low potential for drug-drug interactions<br>and can be used with many common drugs, including:<sup>1</sup>\n</font>\n</span>",
	"Brintellix_55bdc37d6f": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; color: rgb(100, 94, 94); line-height: 1;display:block;\">\n<font style=\"font-size: 11.5px;\">\n\t<b>1.</b>&nbsp;Brintellix<sup>®</sup> Summary of Product Characteristics. 2021.\n</font>\n</span>",
	"Brintellix_55020fce9e": "<p style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; color: rgb(100, 94, 94); line-height: 1.2; display: block;\">\n<font style=\"font-size: 19px;\">\n\tA dose adjustment of Brintellix<sup style=\"\">®</sup> may be considered<br>\n\tif a broad cytochrome P450 inducer (e.g. rifampicin,<br>\n\tcarbamazepine, phenytoin) is added to Brintellix<sup>®</sup><br>\n\ttreatment<sup>1</sup><br>\n\t<span style=\"display: inline-block;padding-top: 10px;\">\n\tA dose reduction of Brintellix<sup style=\"\">®</sup> may be considered if<br>\n\ta strong CYP2D6 inhibitor (e.g. bupropion, quinidine,<br>\n\tfluoxetine, paroxetine) is added to Brintellix<sup>®</sup> treatment<sup>1</sup><br></span>\n\t<span style=\"display: inline-block;padding-top: 10px;\">Concomitant use with non-selective monoamine oxidase<br style=\"\">inhibitors (MAOIs) or selective MAO-A inhibitors<br>is contraindicated<sup>1</sup></span>\n</font>\n</p>",
	"Brintellix_557c842312": "<p style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; color: rgb(100, 94, 94); line-height: 1;display:block;\">\n<font style=\"font-size: 19px;\">\n\tWarfarin and Aspirin<br>\n\t<span style=\"display: inline-block;padding-top: 12px;\">Diazepam </span><br>\n\t<span style=\"display: inline-block;padding-top: 12px;\">Combined oral contraceptives (ethinylestradiol 30 µg/levonorgestrel 150 µg)</span>\n</font>\n</p>",
	"Brintellix_55678ac84d": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;\">\n<font style=\"font-size: 22.5px;\">Drug-drug interactions</font>\n</span>",
	"Brintellix_55fdd67bfb": "Text",
	"Brintellix_55be875978": "<span style=\"font-family: &quot;3_CCMVBT+AvenirNextLTPro-Demi&quot;; color: rgb(84, 122, 129); \">\n<font style=\"font-size: 25px;\">References</font>\n</span>",
	"Brintellix_55b648166d": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 15px;\">\n\t<b>1.&nbsp;</b>Brintellix® Summary of Product Characteristics. 2021.</font></span>",
	"Brintellix_55c1a6da4e": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 15px;\">\n\t<b>2.</b>&nbsp;Cipralex® Summary of Product Characteristics. 2020.\n</font>\n</span>",
	"Brintellix_5550463796": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 15px;\">\n\t<b>3.</b> Effexor® Summary of Product Characteristics. 2020.\n</font>\n</span>",
	"Brintellix_55f1e23f2a": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 15px;\">\n\t<b>4.</b> Seroxat® Summary of Product Characteristics. 2019.\n</font>\n</span>",
	"Brintellix_55d1c51e80": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: #f28700;\"><div style=\"text-align: center;\"><span style=\"font-size: 15px;\">Study Design</span></div>\n</span>",
	"Brintellix_5574e33f5b": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(242, 135, 0); line-height: 1;\"><div style=\"text-align: center;\"><div style=\"text-align: right;\"><font style=\"font-size: 12px;\">Compare to</font></div><div style=\"text-align: right;\"><font style=\"font-size: 12px;\">Escitalopram</font></div></div>\n</span>",
	"Brintellix_554b97dfd3": "Text",
	"Brintellix_55510fc56d": "Text",
	"Brintellix_559d885ea8": "Text",
	"Brintellix_551a28f5ca": "Text",
	"Brintellix_559c65f1a5": "Text",
	"Brintellix_5559a094e6": "Text",
	"Brintellix_554e561b28": "Text",
	"Brintellix_5584828d4f": "Text",
	"Brintellix_55f567a19e": "Text",
	"Brintellix_55037fd419": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); \">\n<font style=\"font-size: 22.5px;\">Low withdrawal rate and discontinuation</font>\n</span>",
	"Brintellix_55f8002199": "Text",
	"Brintellix_5595fc6112": "Text",
	"Brintellix_55fffd4371": "Text",
	"Brintellix_55620b5a61": "Text",
	"Brintellix_55428c631c": "Text",
	"Brintellix_55bd4bfe57": "Text",
	"Brintellix_554fe06ce8": "Text",
	"Brintellix_550093b8a7": ""
}
